A startup wants to revive the Concorde for the generations of flyers that missed out, without the noisy boom and the up to ...

Holdings provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and ...

Stocks eked out gains as traders parsed mixed earnings ahead of jobs data. Bonds pared losses as Treasury Secretary Scott Bessent reiterated his view on a lower path for 10-year yields under the Trump ...

A sense of caution prevailed in the stock market as traders parsed mixed earnings ahead of Amazon.com Inc.’s results and jobs data. Bonds pared losses as Treasury Secretary Scott Bessent reiterated ...

Jan. 24, 8:43 a.m. PSTPresident Donald Trump, who is scheduled to visit Los Angeles on Friday, suggested abolishing the Federal Emergency Management Agency, which is set to cover 100% of the cost ...

This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc ...

Drop in, dependency-free progress bars for your Django/Celery applications. Super simple setup. Lots of customization available. Then in the page you want to show the progress bar you just do the ...

Ascentage’s Wall Street debut is a test of U.S. investors’ interest in the progress China’s biotech sector has made ... Most came from the $100 million Takeda paid to license olverembatinib. The IPO ...

Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long effort to tackle some of its approximately $20 billion dollars of debt and ...

Company has sought to address some of its $20 billion in debt Creditors united to push back against some of the efforts Executives at Bausch Health Cos Inc are shaking up the company’s team of ...

which ended fiscal 2024 above 100%. Given this context, let's now discuss its fundamentals. The bull case for Progress is that the business is expected to deliver 30% y/y revenue growth rates this ...

Ending AIDS actually seems feasible. But, despite such incredible progress, HIV remains strong in much of the world. These tools have not been enough and will not be enough to end the epidemic ...